prilocaine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 2265 721-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propitocaine hydrochloride
  • prilocaine
  • propitocaine
  • (+/-)-Prilocaine
  • prilocaine hydrochloride
  • propitocaine HCl
  • prilocaine HCl
A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.
  • Molecular weight: 220.32
  • Formula: C13H20N2O
  • CLOGP: 1.81
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.13
  • ALOGS: -2.83
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 33.51 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 29 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.72 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 18, 1965 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 152.78 123.26 28 64 9677 2348316
Drug intolerance 136.84 123.26 27 65 13690 2344303

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC N01BB04 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB54 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA EPC N0000175682 Amide Local Anesthetic
FDA Chemical/Ingredient N0000007681 Amides
FDA PE N0000175976 Local Anesthesia
MeSH PA D000777 Anesthetics
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:36333 local anaesthetic
MeSH PA D000779 Anesthetics, Local
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Premature ejaculation indication 44001008 DOID:13709
Local anesthesia indication 386761002
Bacterial septicemia contraindication 10001005 DOID:0040085
Sinus tachycardia contraindication 11092001
Myocardial infarction contraindication 22298006 DOID:5844
Shock contraindication 27942005
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Cerebral arteriosclerosis contraindication 65312002
Diabetes mellitus contraindication 73211009 DOID:9351
Decreased respiratory function contraindication 80954004
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Deficiency of cholinesterase contraindication 360607009
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Denuded skin contraindication 418242004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.81 acidic
pKa2 8.13 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel BLOCKER IC50 4.27 CHEMBL CHEMBL

External reference:

IDSource
4018911 VUID
N0000178903 NUI
C0008846 UMLSCUI
D00553 KEGG_DRUG
046O35D44R UNII
1641 INN_ID
19232009 SNOMEDCT_US
4019902 VANDF
8686 RXNORM
387107003 SNOMEDCT_US
5352 MMSL
d01396 MMSL
004574 NDDF
4906 PUBCHEM_CID
CHEBI:8404 CHEBI
CHEMBL1194 ChEMBL_ID
DB00750 DRUGBANK_ID
CHEMBL1200586 ChEMBL_ID
1786-81-8 SECONDARY_CAS_RN
D011318 MESH_DESCRIPTOR_UI
7276 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0115-1468 CREAM 25 mg TOPICAL ANDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0168-0357 CREAM 25 mg TOPICAL ANDA 14 sections
Prilocaine Hydrochloride with Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9013 INJECTION, SOLUTION 40 mg SUBCUTANEOUS ANDA 12 sections
Prilocaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0362-9014 INJECTION, SOLUTION 40 mg SUBCUTANEOUS ANDA 12 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0591-2070 CREAM 25 mg TOPICAL NDA AUTHORIZED GENERIC 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 0904-6989 CREAM 25 mg TOPICAL ANDA 12 sections
LIVIXIL PAK HUMAN PRESCRIPTION DRUG LABEL 4 15455-9504 KIT 25 mg TOPICAL unapproved drug other 13 sections
LIVIXIL PAK HUMAN PRESCRIPTION DRUG LABEL 4 15455-9504 KIT 25 mg TOPICAL unapproved drug other 13 sections
AgonEaze HUMAN PRESCRIPTION DRUG LABEL 4 15455-9528 KIT 25 mg TOPICAL unapproved drug other 13 sections
AgonEaze HUMAN PRESCRIPTION DRUG LABEL 4 15455-9528 KIT 25 mg TOPICAL unapproved drug other 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 21695-388 CREAM 25 mg TOPICAL ANDA 14 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 33261-591 CREAM 25 mg TOPICAL ANDA 11 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 42254-195 CREAM 25 mg TOPICAL ANDA 11 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 50090-2167 CREAM 25 mg TOPICAL ANDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 50383-667 CREAM 25 mg TOPICAL ANDA 11 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 52565-007 CREAM 25 mg TOPICAL ANDA 12 sections
LIDOCAINE AND PRILOCAINE HUMAN PRESCRIPTION DRUG LABEL 2 54868-5194 CREAM 25 mg TOPICAL ANDA 14 sections
Prizotral HUMAN PRESCRIPTION DRUG LABEL 2 59088-705 KIT 25 mg None NDA authorized generic 14 sections
Nuvakaan HUMAN PRESCRIPTION DRUG LABEL 2 59088-706 KIT 25 mg None NDA authorized generic 13 sections
Aprizio Pak HUMAN PRESCRIPTION DRUG LABEL 2 59088-711 KIT 25 mg None NDA authorized generic 12 sections
Prilopentin HUMAN PRESCRIPTION DRUG LABEL 3 59088-739 KIT 25 mg None ANDA 21 sections
Prilo Patch HUMAN PRESCRIPTION DRUG LABEL 3 59088-741 KIT 25 mg None NDA authorized generic 13 sections
Lipritin HUMAN PRESCRIPTION DRUG LABEL 3 59088-753 KIT 25 mg None ANDA 21 sections
DermacinRx Empricaine HUMAN PRESCRIPTION DRUG LABEL 2 59088-810 KIT 25 mg None NDA authorized generic 13 sections
DermacinRx Prizopak HUMAN PRESCRIPTION DRUG LABEL 2 59088-873 KIT 25 mg None NDA authorized generic 13 sections
LIDOCAINE AND PRILOCAINE HUMAN PRESCRIPTION DRUG LABEL 2 61919-443 CREAM 25 mg TOPICAL NDA 13 sections
Lidocaine and Prilocaine HUMAN PRESCRIPTION DRUG LABEL 2 63187-577 CREAM 25 mg TOPICAL NDA authorized generic 13 sections
Oraqix HUMAN PRESCRIPTION DRUG LABEL 2 66312-110 GEL 25 mg PERIODONTAL NDA 18 sections
Citanest Forte HUMAN PRESCRIPTION DRUG LABEL 2 66312-540 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA 12 sections
Citanest Forte DENTAL HUMAN PRESCRIPTION DRUG LABEL 2 66312-580 INJECTION, SOLUTION 40 mg PARENTERAL ANDA 12 sections